AzTrials
AzTrials

Achalasia CardiaNCT07167355

Comparison of Balloon Dilatation and Per Oral Endoscopic Myotomy in Children With Achalasia Cardia

A study testing POEM and BALLOON DILATATION in people with Achalasia Cardia, run by Asian Institute of Gastroenterology, India.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

To compare the efficacy of balloon dilatation (BD) and per oral endoscopic myotomy (POEM) in improving the symptoms of children with achalasia in short and long term Presently most guidelines such as American Society for Gastrointestinal Endoscopy (ASGE) or European Society for Gastrointestinal Endoscopy (ESGE)… Read more about this study

Who is it for?
Ages 3 to 17 years
Conditions the study is for
Achalasia Cardia
What is being tested?
POEM and BALLOON DILATATION
Could I receive a placebo?
No, everyone receives an active treatment
How many people
70 participants
Where
No sites listed yet
Study dates
3 Sep 2025to 15 Jul 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • -> All children of age 3-17 years diagnosed as a case of achalasia cardia

Who cannot join

  • Children who had previously underwent BD, LHM or POEM
  • Type 3 achalasia cardia. In children in whom HRM is not possible, if symptoms or barium oesophagogram is classical of type 3 achalasia, they will be excluded.
  • Prior history of oesophageal or gastric surgery
  • Coagulopathy
  • Alternative diagnosis

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Dr.Srinivas srinidhi vadlapudi, MD, DM contact

96525221524

srinivas.vadlapudi19@gmail.com

About this study

Official title: Comparison of Outcome of Balloon Dilatation and Per Oral Endoscopic Myotomy in Children With Achalasia Cardia. A Randomized Control Cross Over Trial

To compare the efficacy of balloon dilatation (BD) and per oral endoscopic myotomy (POEM) in improving the symptoms of children with achalasia in short and long term Presently most guidelines such as American Society for Gastrointestinal Endoscopy (ASGE) or European Society for Gastrointestinal Endoscopy (ESGE) recommend POEM or LHM or BD for the management of achalasia cardia based on the institutional expertise and patient preference. Only the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) recommend POEM or LHM over PBD for the management of achalasia in children. This is due to the lack of pediatric randomised control trial comparing the efficacy and safety of the two methods both in long and short term.

Children 3-18 years of age diagnosed as a case of achalasia cardia Place of trial: Department of medical gastroenterology, AIG Hospitals, Gachibowli and Somajiguda/Banjara Hills Duration of the trial: 3-4 years Sample size: 70 (35 each arm) Inclusion criteria: All children diagnosed as a case of achalasia cardia aged 3-18 years Exclusion criteria: Children who have undergone prior BD or POEM or Heller's myotomy. Type 3 achalasia cardia. Prior oesophageal/gastric surgery. Coagulopathy. Patients refusing consent for the trial.

Read more

Primary outcome: Percentage of children with achalasia cardia achieving a clinical success of BD and POEM at 12 months post intervention (clinical success is Eckardt score ≤ 3 and timed barium esophagogram (TBE) showing a holdup at gastroesophageal junction of <5cm at 5 minutes without requirement of further intervention) Secondary outcomes: Major and minor treatment complications, percentage patients developing gastroesophageal reflux disease, procedure time and improvement in growth Randomization: A stratified block randomization shall be performed using computer generated random number tables BD arm: Children <7 years of age will under 1-2 sessions of BD 1month apart with CRE 20mm balloon. Children 7-17 years of age will undergo 1-2 sessions of BD with Rigiflex II, Achalasia balloon dilator (30mm followed by 35mm).

POEM arm: Children 3-17 years of age will undergo 1 session of POEM as per the unit protocol.

Outcomes will be assessed at 3,6,12 months of the index procedure Crossover: If Eckardt score >3 and TBE showing a stasis of >5cm at 5 minutes, treatment is considered to have failed and crossover will be offered Endpoints: One year of follow up from the initial intervention or one year of follow up of the crossover intervention (in case of treatment failure), major complications.

Interim analysis: Following completion of follow up of 50% of the trial participants Early termination of trial: In case of any treatment modality having >10% major complications or during interim analysis one treatment modality significantly better than other (p<0.003)

Read the detailed description

To compare the efficacy of balloon dilatation (BD) and per oral endoscopic myotomy (POEM) in improving the symptoms of children with achalasia in short and long term

Background:

Achalasia means "failure to relax". Achalasia cardia is a rare oesophageal motility disorder that occurs due to degeneration of the inhibitory myentric plexus of neurons of the oesophagus. This disorder is characterised by failure of relaxation of the lower oesophageal sphincter (LES), increased basal tone of the LES and absence of peristalsis in the oesophagus. All of these result in difficulty in passage of a food bolus from the oesophagus into stomach. Achalasia occurs in 0.1-0.18/100,000 per children per year.(1,2) Most patients present with symptoms of vomiting, dysphagia, chest pain and regurgitation. However, in children extra oesophageal symptoms such as chronic cough or aspiration is common. Smaller children may present with refusal to feed and failure to thrive. Achalasia cardia is a component of Allgrove syndrome and presents at an early age.(3) Treatment options for achalasia cardia include calcium channel blockers, botulinum injection, pneumatic balloon dilatation (BD), laparoscopic Hellers myotomy (LHM) and peroral endoscopic myotomy (POEM). BD, LHM and POEM are superior to the other therapies and should be offered to the patients when they are fit for the procedure. The type of achalasia, expertise of the centre and the patient preference should be taken into consideration before deciding on the modality of the treatment.(4) For type 3 achalasia cardia, POEM has been found to be superior when compared to BD or LHM.(4-7) However, for the other 2 types most guidelines don't provide a clear preference of one modality over the other. Major differences in the outcomes were not identified in between LHM and POEM in the systematic reviews and randomised control trials among type 1 and 2 achalasia.(8,9) Randomised control trials in adults have shown POEM to be superior to BD.(10,11) However, prospective comparative trials in children are lacking. A retrospective study by Tan Y et al showed BD to be as effective as POEM in short term (upto 1 year) but POEM was more effective on longer follow up.(12) Due to limited clinical trials and small sample sizes most guidelines advocate either of BD, LHM, POEM as the first line treatment modality for managing a patient with achalasia cardia on a case to case basis.(4-6) However, Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) recommends for POEM or LHM as the preferred modality over BD even in type 1 and 2 achalasia cardia. SAGES guidelines though recognises the lack of pediatric randomised trials comparing the three modalities of treatment and recommends for comparative pediatric studies in the future.(7) BD is also not standardised in children and there is no recommendation on the size of balloon to be used at a particular age. Commonly most studies treat children more than 6 years of age similar to adults. There is a lack of clarity on the treatment of children below this age. Multiple studies have used different balloons of different sizes with varying success. The absence of standard Rigiflex balloon smaller than 30mm complicates the matter. POEM however, has been found to be safe in children and has been performed in smaller children with good success.(13-20) However, due to technical difficulty it is not yet being performed as a standard of care at all centres. Thus, with these deficiencies in the literature, we planned for a randomised control trial to compare the outcomes of BD and POEM in children.

Rationale Presently most guidelines such as American Society for Gastrointestinal Endoscopy (ASGE) or European Society for Gastrointestinal Endoscopy (ESGE) recommend POEM or LHM or BD for the management of achalasia cardia based on the institutional expertise and patient preference. Only the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) recommend POEM or LHM over PBD for the management of achalasia in children. This is due to the lack of paediatric randomised control trial comparing the efficacy and safety of the two methods both in long and short term.

Study participants Children 3-18 years of age diagnosed as a case of achalasia cardia Design: Randomized control crossover trial Place of trial: Department of medical gastroenterology, AIG Hospitals, Gachibowli and Somajiguda.

Duration of the trial: 3-4 years Sample size: 70 (35 each arm)

Randomization: A stratified block randomization shall be performed using computer generated random number tables BD arm: Children <7 years of age will under 1-2 sessions of BD 1month apart with CRE 20mm balloon. Children 7-17 years of age will undergo 1-2 sessions of BD with Rig flex II, Achalasia balloon dilator (30mm followed by 35mm).

POEM arm: Children 3-17 years of age will undergo 1 session of POEM as per the unit protocol.

Outcomes will be assessed at 3,6,12 months of the index procedure Crossover: If Eckardt score >3 and TBE showing a stasis of >5cm at 5 minutes, treatment is considered to have failed and crossover will be offered Endpoints: One year of follow up from the initial intervention or one year of follow up of the crossover intervention (in case of treatment failure), major complications.

Interim analysis: Following completion of follow up of 50% of the trial participants Early termination of trial: In case of any treatment modality having >10% major complications or during interim analysis one treatment modality significantly better than other (p<0.003)

Being tested
POEM, BALLOON DILATATION
Medical subject headings
Esophageal Achalasia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • POEMProcedure or surgery

    Children randomised to POEM arm will undergo a single session of POEM following an overnight fast. The procedure will be done in supine position under general anaesthesia. A gastroscope (Olympus GIF-HQ190) with a transparent tapered cap fit at its distal end will be used. A mucosal bleb will be created using a 21G sclerotherapy needle and a solution of saline with indigo-carmine dye. A posterior approach will be followed in all patients. A small mucosal incision (2-3mm) will be made using a needle knife and enlarged using an insulated tip knife (2-3cm). The submucosal tunned will then be entered and the submucosal fibres will be cleared using a triangular tip knife (TriangularTipKnife J, Olympus). Full thickness will be performed in all patients. Length of the myotomy will be ~3cm in the oesophagus and ~2cm in the cardia of the stomach. Minor bleeding will be controlled using coagulation forceps. Mucosal injury and resistance at the gastroesophageal junction will be examined. Mucosal i

  • BALLOON DILATATIONProcedure or surgery

    Children randomised to BD arm will undergo BD of 30mm (Rigiflex II, Achalasia balloon dilators, Boston Scientific) following an overnight fast. The balloon will be positioned at the gastroesophageal junction and inflated to a diameter of 30mm with a pressure of 5psi initially and gradually the pressure will be increased to a maximum of 15 psi till the disappearance of waist fluoroscopically. A note will be made at the pressure at which the waist disappears and will be maintained for 1 minute. One month after the initial session, if the Eckardt score >3 or if the TBE shows a barium column of >5cm at 5 minutes, a second session of BD will be done using a 35mm balloon.

    These children will be kept nil per oral for 4 hours post procedure. They will be observed for signs of perforation (crepitus, hemodynamic instability, chest pain). If they are stable, a clear liquid (water) will be provided. If there is no pain, they will be discharged with an advise to follow soft diet for a day

Study groups in NCT07167355
Study groupRoleWhat they receive
POEMActive comparatorNot described
Receives: Procedure: POEM
BALLOON DILATATIONActive comparatorChildren randomised to BD arm, will undergo BD of 20mm (Controlled radial expansion [CRE], Boston Scientific) following an overnight fast. The balloon will be positioned at the gastroesophageal junction and inflated to a diameter of 20mm and a note will be made of whether the waist has disappeared or not. A repeat session of BD will be done after 1 month if TBE reveals a holdup of >5cm at 5 minutes. In this subgroup of children calculating Eckardt score will be difficult and unreliable. Balloon dilatation (children 7-17 years of age): Children randomised to BD arm will undergo BD of 30mm (Rigiflex II, Achalasia balloon dilators, Boston Scientific) following an overnight fast. The balloon will be positioned at the gastroesophageal junction and inflated to a diameter of 30mm with a pressure of 5psi initially and gradually the pressure will be increased to a maximum of 15 psi till the disappearance of waist fluoroscopically. A note will be made at the pressure at which the waist disappe
Receives: Procedure: BALLOON DILATATION

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary: Clinical success is defined as • Eckardt score ≤ 3 • Absence of need for further endoscopic or surgical treatments to maintain Eckardt score ≤ 3 and • TBE showing oesophageal stasis of <5cm at 5minutes

    • Eckardt score is calculated based on chest pain, regurgitation, dysphagia and weight loss

    Measured: 12 month

Secondary outcomes (4)
  1. Secondary objective:

    • Major treatment related complications (treatment related complications were considered to be major if there was an unplanned hospital admission for > 24 hours, prolongation of a planned hospital admission, requirement of intensive care unit admission, requirement for a blood transfusion or need for additional endoscopic procedures for the management of the same)

    Measured: 12 month

  2. Percentage of patients developing gastroesophageal reflux disease

    Evidence of reflux esophagitis on upper gastrointestinal endoscopy

    Measured: 12 months

  3. Minor complication rate

    Number of patients developing minor complications (other than major complications)

    Measured: 12 months

  4. Change in growth

    improvement or worsening of growth following intervention

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Sep 2025
  2. Study start3 Sep 2025 (estimated)
  3. Primary completion22 Oct 2027 (estimated)
  4. Study completion15 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07167355
Sponsor's protocol ID
COS 1
Status last verified
Sep 2025
First submitted
15 Aug 2025
Last updated
11 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Tang X, Gong W, Deng Z, Zhou J, Ren Y, Zhang Q, Chen Z, Jiang B. Usefulness of peroral endoscopic myotomy for treating achalasia in children: experience from a single center. Pediatr Surg Int. 2015 Jul;31(7):633-8. doi: 10.1007/s00383-015-3717-9. Epub 2015 May 9.

    PubMed 25957132
  • de Moura ETH, Jukemura J, Ribeiro IB, Farias GFA, de Almeida Delgado AA, Coutinho LMA, de Moura DTH, Aissar Sallum RA, Nasi A, Sanchez-Luna SA, Sakai P, de Moura EGH. Peroral endoscopic myotomy vs laparoscopic myotomy and partial fundoplication for esophageal achalasia: A single-center randomized controlled trial. World J Gastroenterol. 2022 Sep 7;28(33):4875-4889. doi: 10.3748/wjg.v28.i33.4875.

    PubMed 36156932
  • Mayberry JF, Mayell MJ. Epidemiological study of achalasia in children. Gut. 1988 Jan;29(1):90-3. doi: 10.1136/gut.29.1.90.

    PubMed 3343019

Questions about this trial

What is this clinical trial studying?

A study testing POEM and BALLOON DILATATION in people with Achalasia Cardia, run by Asian Institute of Gastroenterology, India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Dr.Srinivas srinidhi vadlapudi, MD, DM (96525221524, srinivas.vadlapudi19@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary: Clinical success is defined as • Eckardt score ≤ 3 • Absence of need for further endoscopic or surgical treatments to maintain Eckardt score ≤ 3 and • TBE showing oesophageal stasis of <5cm at 5minutes (time frame: 12 month). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07167355, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in